The Only True Biotech Dividend Stock

Dividend stocks are hard to come by in the biotech space. There are plenty of pharmas that offer dividends, but finding a biotech stock that offers a dividend is a bit challenging.

The one and only
In fact, there's really only one biotech dividend stock: Amgen (NASDAQ: AMGN  ) . The company started offering a dividend in 2011, so it doesn't exactly have a long history of offering a dividend. Even so, it seems like Amgen is fully committed to being a dividend stock; it raised its dividend in 2012 and again this year. The dividend now sits at $1.90 per share, 68% higher than where it started in 2011.

At a yield of just 1.9%, you're not going to be buying Amgen solely for its dividend; it'll take some capital appreciation to justify owning the dividend stock. Still, it's a nice payout when growth is hard to come by.

Why the other big biotechs aren't dividend stocks
True confession: I started this article with a plan to argue that the other three big biotechs -- Biogen Idec (NASDAQ: BIIB  ) , Celgene (NASDAQ: CELG  ) , and Gilead Sciences (NASDAQ: GILD  ) -- should also offer a dividend.

Then I made the following chart.


Free Cash Flow TTM (in millions)


Biogen Idec












Source: S&P Capital IQ. TTM = trailing 12 months, FCF = free cash flow, P = price.

The second column is essentially what the dividend yield could be if the company spent all of its free cash flow on a dividend. No company would do that, but it shows how little of its free cash flow Amgen is using on its dividend. If the other three wanted to be dividend stocks with yields of 2%, they'd have to dedicate half or more of their free cash flow.

That clearly wouldn't be a good idea. Companies need that cash to license drugs and make acquisitions to supplement the pipeline; internal R&D can only take companies so far.

Priced for growth
Amgen is different from the other three large biotechs because investors have given up expecting massive growth from the company. Biogen, Celgene, and Gilead are still being priced like they have substantial growth left. It doesn't make sense for them to become dividend stocks until investors are pricing them like a slow-growth pharma.

The obvious compromise is for companies to repurchase shares, which give the biotech companies a little more freedom with their free cash flow than dividends that investors would come to expect. If more M&A opportunities arise, companies can cut back on purchases accordingly.

All three have repurchased shares over the last few years. Celgene, for example, recently completed a $2.5 billion stock repurchase and reupped for another $3 billion.

While I'm sure there are a lot of dividend investors that would like to have more options for biotech dividend stocks, at least the companies aren't hoarding shareholders' cash.

If you're looking for additional ways to diversify into dividend-paying stocks, The Motley Fool's special report "Secure Your Future With 9 Rock-Solid Dividend Stocks" is a great way to kick-start your search. Just click here to get your free copy today.

Read/Post Comments (3) | Recommend This Article (7)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 26, 2013, at 8:41 PM, drugstock2 wrote:

    Abbvie (ABBV) is the only true biotech dividend stock.

  • Report this Comment On June 29, 2013, at 6:20 PM, wjcoffman wrote:

    "Biogen, Celgene, and Gilead are still being priced like they have substantial growth left. It doesn't make sense for them to become dividend stocks until investors are pricing them like a slow-growth pharma."

    No big surprise there. GILD has nearly tripled in 3 years. GILD: Keep the dividend and continue re-investing in the company.

    If you want dividend go hunting for them in industries where they're typically found and cultivated: electrical power companies for example. When was the last time a power company went out of business? Closest to a sure thing that you'll find I'd proffer.

  • Report this Comment On December 11, 2014, at 8:02 PM, Oily2 wrote:

    I guess AbbVie is considered a major drug manufacturer but I consider it a biotech with a good yield. I'm buying it biweekly through their transfer agent at a whooping $25 a pop with no fees and free DRIP. I'd buy the others listed if they had free purchases too.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2510537, ~/Articles/ArticleHandler.aspx, 9/29/2016 4:25:14 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,143.45 -195.79 -1.07%
S&P 500 2,151.13 -20.24 -0.93%
NASD 5,269.15 -49.39 -0.93%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/29/2016 4:00 PM
AMGN $165.45 Down -4.26 -2.51%
Amgen CAPS Rating: ****
BIIB $305.78 Down -4.77 -1.54%
Biogen CAPS Rating: *****
CELG $102.77 Down -3.06 -2.89%
Celgene CAPS Rating: *****
GILD $77.86 Down -1.11 -1.41%
Gilead Sciences CAPS Rating: *****